Reviewer's report

Title: Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

Version: 2
Date: 27 March 2015

Reviewer: Nagaaki Tanaka

Reviewer's report:

Dr. Umezawa and colleagues reported that sitagliptin could be a treatment option for elder patients with type 2 diabetes as the efficacy and safety were concerned. This observational study is large-scale and informative, however, there seems to be several questions to be answered.

Major Compulsory Revisions
1. The authors should clearly describe the definition of hypoglycemia.
2. The authors should mention the target level of treatment for the patients. The treatment of the elder patients might be less stringent than that of the younger in clinical settings, which could result in less hypoglycemia in the elder patients.
3. The limitation of this study should be stated.
4. The authors should describe the dose of sulfonylureas (such as % of maximum dose).
5. The authors should discuss the reason why the elder patients could reach the same target level of glycemia as the younger patients without hypoglycemia when sitagliptin was administered.

Discretionary Revisions
1. Clinical characteristics of patients with SU and sitagliptin should also be presented.
2. Other adverse events than hypoglycemia might be stated, if reported.
3. The authors could discuss the characteristics of patients with incidence of hypoglycemia.
4. In Conclusions, “without causing weight gain” should be corrected to “without hypoglycemia”.
5. The definition of postprandial blood glucose should be stated.

Level of interest: An article of importance in its field

Quality of written English: Not suitable for publication unless extensively edited

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.
Declaration of competing interests:

I declare that I have no competing interests.